1. ALLA AKTIER
  2. NYHETER
  3. LIDDS

LIDDS

Nyheter LIDDS Nyheter alla bolag

LIDDS’ Annual Report 2024 published

MARKN.

GOTHENBURG, SWEDEN – The 2024 Annual report of LIDDS AB (publ) is now available on the company website.

The annual report is available in Swedish in PDF format on the company website at: https://liddspharma.com/en/investors/financial-reports/.

Copies can be ordered from LIDDS AB, co Excore, Kungsportsavenyen 22, 411 36 Göteborg or by e-mail: info@liddspharma.com.

For additional information, please contact

Mats Wiking, CEO and CFO
Phone: +46 (0)70 620 04 00
E-mail: mats.wiking@liddspharma.com

LIDDS’ Certified Adviser is Redeye AB

LIDDS in brief:

LIDDS is a Swedish pharmaceutical company focused on the development of oncology drugs. LIDDS has a proprietary drug delivery technology, NanoZolid®, on which several projects are based. With NanoZolid, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release and with minimal negative side-effects. In addition to these projects, LIDDS develops proprietary drug candidate NOV202 that have shown very good results in pre-clinical studies. The company is listed on Nasdaq First North Growth market.

Attachments

Årsredovisning 2024 LIDDS AB (publ)
Revisionsberättelse 2024 LIDDS AB (publ)

Datum 2025-05-06, kl 08:00
Källa MFN
Bifogade filer
Årsredovisning 2024 LIDDS AB (publ)
Revisionsberättelse 2024 LIDDS AB (publ)
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!